**Measure 140: Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement**

**Reporting Options:** Claims and Registry

**Quality Domain:** Effective Clinical Care

**Description:** Percentage of patients aged 50 years and older with a diagnosis of AMD and/or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of AMD

**Instructions:** This measure is to be reported a minimum of once per reporting period for AMD patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with AMD will submit this measure.

**Definition:**
**Counseling:** Documentation in the medical record should include a discussion of risk or benefits of the AREDS formulation. Counseling can be discussed with all patients with AMD, even those who do not meet the criteria for the AREDS formulation, patients who are smokers (beta-carotene can increase the risk for cancer in these patients) or other reasons why the patient would not meet criteria for AREDS formulation as outlined in the AREDS. The ophthalmologist can explain why these supplements are not appropriate for their particular situation. Also, given the purported risks associated with antioxidant use, patients would be informed of the risks and benefits and made their choice based on valuation of vision loss vs. other risks. As such, the measure seeks to educate patients about overuse as well as appropriate use.

**Antioxidant Vitamin and Mineral Supplements Used in the AREDS**

<table>
<thead>
<tr>
<th>Supplement</th>
<th>Daily Dose (see note below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin C</td>
<td>500 mg</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>400 IU</td>
</tr>
<tr>
<td>Lutein/zeaxanthin</td>
<td>10 mg/2 mg</td>
</tr>
<tr>
<td>Zinc oxide</td>
<td>80 mg or 25 mg</td>
</tr>
<tr>
<td>Cupric oxide</td>
<td>2 mg</td>
</tr>
</tbody>
</table>

**Note:** These doses are not those listed on the commercially available vitamin/mineral supplements because of a change in labeling rules by the U.S. Food and Drug Administration that specifies that the doses must reflect the amounts available at the end of the shelf life.
**Category II Codes:**

4177F Counseling about the benefits and/or risks of the Age-Related Eye Disease Study (AREDS) formulation for preventing progression of age-related macular degeneration (AMD) provided to patient and/or caregiver(s);

or

4177F 8P AREDS counseling not performed, reason not otherwise specified

**CPT Codes:**

92002, 92004, 92012, 92014, 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337

**Diagnosis Codes:**

Diagnosis for AMD (ICD-9-CM) [for use 1/1/2015-9/30/2015]: 362.50, 362.51, 362.52

Diagnosis for AMD (ICD-10-CM) [for use 10/01/2015-12/31/2015]: H35.30, H35.31, H35.32